CD8A and cancer: To evaluate the potential of NKG2A as a target for the delivery of an IL-2Rβγ agonist to tumor-infiltrated CD8+ T and NK cells, the expression profile of NKG2A in immune cells derived from tumor tissues of cancer patients was analyzed and compared to that of PD-1, which is usually used as a target for the delivery of IL-2Rβγ agonist.